Last reviewed · How we verify
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose)
Variant-adapted BNT162b2 (Omicron XBB.1.5) is a 10 microgram dose vaccine developed by Pfizer Inc. It is marketed for the prevention of COVID-19 in individuals 12 years of age and older, and in individuals 6 months through 11 years of age. The vaccine has generated $21.2B in revenue. Its mechanism is not specified on Wikipedia. The vaccine is a variant-adapted version of the BNT162b2 vaccine, which is a type of mRNA vaccine. This variant is specifically designed to target the Omicron XBB.1.5 variant of the SARS-CoV-2 virus. The vaccine's clinical differentiation and pipeline developments are not specified.
At a glance
| Generic name | variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose |
|---|---|
| Sponsor | Pfizer |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of COVID-19 in individuals 12 years of age and older
- Prevention of COVID-19 in individuals 6 months through 11 years of age
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pain/NSAID medications
- Anticoagulant medications
- Antiplatelet medications
- Thrombolytic medications
- Live vaccines
- Interferon-alpha
- Interferon-beta
- Interferon-gamma
- Immunosuppressants
- Corticosteroids
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: